Skip to main content

Table 1 Comparison of 1 year treatment response between IL-22-high and IL-22-low group

From: Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

Variables IL-22 low IL-22 high p value
TNF-i treated group n=12 n-12  
DAPSA-REM 8(66.7) 5(41.6) 0.4136
DAPSA-LDA 9(75.0) 10(83.3) 1.0000
Minimal Disease Activity 8(66.7) 9(75.0) 1.0000
PASI 75 7/11(63.6) 5/11(45.4) 0.6699
PASI 90 9/11(81.8) 6 /11(54.5) 0.3615
IL-17-i-treated group n=10 n=13  
DAPSA-REM 9(90) 2(15.3) *0.0006*
DAPSA-LDA 10(100) 12(92.3 %) 1.0000
Minimal Disease Activity 10(100) 6(46.1) *0.0075*
PASI 75 7/9(77.8) 7/9(77.8) 1.0000
PASI 90 7/9(77.8) 7/9(77.8) 1.0000
  1. Data are expressed as number (%)
  2. TNF-i TNF inhibitors, IL-17-i IL-17 inhibitors, DAPSA disease activity in psoriatic arthritis, LDA low disease activity, REM remission, PASI Psoriasis Area and Severity Index
  3. *p<0.05, by chi-square test